Personalized Cell Therapy Market Report 2026

The personalized cell therapy market size has grown exponentially in recent years. It will grow from $20.83 billion in 2025 to $25.42 billion in 2026 at a compound annual growth rate (CAGR) of 22.1%. The growth in the historic period can be attributed to limited availability of autologous cell therapies, high dependency on conventional treatments, lack of advanced biomanufacturing infrastructure, slow regulatory approvals, low patient awareness of personalized therapies.

The personalized cell therapy market size is expected to see exponential growth in the next few years. It will grow to $56.46 billion in 2030 at a compound annual growth rate (CAGR) of 22.1%. The growth in the forecast period can be attributed to growing demand for autologous and allogeneic cell therapies, increasing adoption of ai-driven treatment optimization, rising government and private funding for cell therapy research, expanding applications in cancer, cardiovascular, and autoimmune diseases, growing partnerships between biotech firms and research institutes. Major trends in the forecast period include increasing adoption of genomic-based cell therapy approaches, rising implementation of personalized immunotherapy techniques, growing integration of digital platforms for cell therapy management, increasing use of ai and big data in cell therapy research, rising investment in biomanufacturing and scalable cell production.

The increasing incidence of neurological disorders is expected to support the growth of the personalized cell therapy market in the coming years. Neurological disorders comprise a range of conditions that affect the brain, spinal cord, and nerves, resulting in symptoms such as impaired movement, cognitive decline, and sensory abnormalities. The rising occurrence of these disorders is associated with aging populations, environmental stress factors, and lifestyle changes that contribute to higher rates of neurodegenerative diseases. Personalized cell therapy plays a critical role in addressing neurological disorders by providing customized treatments tailored to individual patient needs, with the potential to repair damaged neural tissue and improve outcomes in complex, patient-specific conditions. For instance, in April 2024, according to *Neurology*, a US-based publication of the American Academy of Neurology, global cases of brain and neurological disorders are projected to increase by around 22% by 2050. Therefore, the rise in neurological disorders is driving the growth of the personalized cell therapy market.

Major companies operating in the personalized cell therapy market are focusing on the development of advanced solutions such as closed-system sterile manufacturing to enable contamination-free processing of patient-derived cells from collection through final formulation. Closed-system sterility involves processing cells without exposure to the external environment, ensuring sterility throughout the manufacturing and handling stages. For example, in March 2025, Limula SA, a Switzerland-based company specializing in advanced cell therapy solutions, launched LimONE, an automated cell therapy manufacturing platform designed to streamline the production of personalized therapies such as CAR-T and hematopoietic stem cell treatments. This platform offers a closed-system sterile workflow and supports more consistent and reproducible production of patient-specific cell therapies.

In March 2025, Bristol Myers Squibb (BMS), a US-based pharmaceutical company focused on innovative medicines, acquired 2seventy bio, Inc. for an undisclosed amount. Through this acquisition, BMS aims to strengthen its personalized cell therapy capabilities, particularly in oncology, by obtaining full ownership of Abecma (idecabtagene vicleucel), a BCMA-directed CAR T therapy. This move is intended to advance the development and commercialization of patient-specific cell therapies. 2seventy bio, Inc. is a US-based biotechnology company specializing in personalized and engineered CAR T cell therapies for hematologic malignancies.

Major companies operating in the personalized cell therapy market are Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Nkarta Therapeutics Inc., Intellia Therapeutics Inc., Tessa Therapeutics Pte Ltd, Atara Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences Inc., Editas Medicine Inc., Cellectis S.A., Gracell Biotechnologies Inc., Mesoblast Limited, Fate Therapeutics Inc., Athersys Inc., Bellicum Pharmaceuticals Inc., Celyad Oncology SA, Century Therapeutics Inc., Gamida Cell Ltd., CRISPR Therapeutics AG, Allogene Therapeutics Inc., Bluebird bio Inc., Autolus Therapeutics plc.

North America was the largest region in the personalized cell therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the personalized cell therapy market by increasing the cost of imported bioreactors, cell processing kits, and genetic engineering reagents, affecting hospitals, specialty clinics, and homecare services primarily in North America, Europe, and Asia-Pacific. While tariffs have raised operational costs and slowed imports, they have also encouraged local manufacturing, innovation in scalable cell production, and adoption of cost-efficient therapies, ultimately supporting domestic market growth.

The personalized cell therapy market research report is one of a series of new reports that provides personalized cell therapy market statistics, including personalized cell therapy industry global market size, regional shares, competitors with a personalized cell therapy market share, detailed personalized cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the personalized cell therapy industry. This personalized cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Personalized cell therapy is a medical treatment approach in which a patient’s own cells, or cells specifically customized for that individual, are used to treat a disease or condition. This therapy is tailored to the patient’s unique biological characteristics and often involves modifying or manipulating cells to improve their therapeutic effectiveness. A key benefit of personalized cell therapy is the reduced risk of rejection and adverse immune reactions, as the treatment is designed to be compatible with the patient’s body.

The main types of personalized cell therapy include lymphocytes, mesenchymal stem cells, hematopoietic stem cells, and others. Lymphocytes are a category of white blood cells that play a vital role in the immune system by helping the body combat disease. Personalized cell therapy employs techniques such as platelet transfusions, bone marrow transplantation, packed red blood cell transfusions, and organ transplantation, and is used to treat conditions including cardiovascular diseases, neurological disorders, inflammatory diseases, diabetes, cancer, and others. These therapies are utilized by various end users, such as hospitals, homecare settings, specialty clinics, and others.

The personalized cell therapy market consists of revenues earned by entities by providing services such as c car-t cell therapy, stem cell transplantation, tissue regeneration, gene editing therapies and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized cell therapy market also includes sales of personalized cancer vaccines, cell therapy kits and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.